Avicanna Reports Q2 2024
Q2 2024 revenue of $6.1 million an increase of 85% over Q2 2023
Completion of two real world evidence trials on Epidermolysis Bullosa and Musculoskeletal Pain
NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.